Почетна › Рак на бели дробови › Пенсилванија › Pittsburgh
Клинички испитувања за Рак на бели дробови во Pittsburgh, PA
23 студии за Рак на бели дробови бараат учесници на локации во и околу Pittsburgh (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Се регрутираФаза 3
- Bryn Mawr Hospital, Bryn Mawr · на 11 милји
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Се регрутираФаза 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Се регрутираФаза 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- и уште 11
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Се регрутираФаза 3
- Bryn Mawr Hospital, Bryn Mawr · на 11 милји
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Се регрутира
- UPMC Hillman Cancer Center, Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Се регрутираФаза 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · на 11 милји
- UPMC Hillman Cancer Center - Monroeville, Monroeville · на 11 милји
- и уште 1
A Registry for People With Lung Cancer
Се регрутираНабљудувачка студија
- ALLEGHENY HEALTH NETWORK (Data Collection Only), Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Се регрутираФаза 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Се регрутираФаза 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Се регрутираФаза 1/2
- Allegheny Health Network, Pittsburgh
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Се регрутираФаза 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Се регрутираФаза 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Се регрутираФаза 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Се регрутираФаза 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Се регрутираФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Се регрутираФаза 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Се регрутираФаза 2
- Allegheny General Hospital, Natrona Heights · на 19 милји
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Се регрутираФаза 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Се регрутираФаза 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- и уште 11
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- и уште 9
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Се регрутираНабљудувачка студија
- Allegheny Health Network, Pittsburgh
Detection of Genetic Markers of Lung Cancer
Се регрутираНабљудувачка студија
- Hillman Cancer Center, Pittsburgh
Испитувања за Рак на бели дробови во други градови
- Houston, TX78 студии
- Boston, MA62 студии
- New York City, NY60 студии
- Los Angeles, CA45 студии
- Arlington, VA41 студија
- Washington, DC41 студија
- Chicago, IL41 студија
- Baltimore, MD40 студии
- Nashville, TN40 студии
- St. Louis, MO39 студии
- Columbus, OH37 студии
- Philadelphia, PA36 студии
Други студии во Pittsburgh
- Рак на бели дробови со не-мали клетки48 студии
- Рак (сите типови)41 студија
- Рак на дојка39 студии
- Колоректален карцином32 студии
- Метастатски карцином31 студија
- Меланом31 студија
- Карцином на јајниците30 студии
- Рак на ендометриумот23 студии
- Рак на простата23 студии
- Сквамозноклеточен карцином на глава и врат22 студии
- Шлог22 студии
- Депресија22 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.